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reduced diastolic blood pressure (r=–0.55; p=0.01). In the non diabetic group,
tHcy levels were negatively correlated with HTase activities (r=0.75; p=0.00)
and diet score (r=–0.70; p=0.01) while HTase activities were positively corre-
lated with diet score (r= 0.75; p= 0.00). 
Conclusion: Elevated homocysteine in diabetic patients may partly be
explained by the diminished HTase and could be considered as an additional
risk factor for cardiovascular events. Adherence to Mediterranean diet could
be the first efficient step to prevent these complications.
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Left main coronary stenting in a non surgical octogenarian popula-
tion: a possible approach
Ziad Dahdouh [Orateur] , Vincent Roule, Mathieu Bignon, Guillaume
Malcor, Rémi Sabatier, Thérèse Lognoné, Gilles Grollier
CHU de Caen, Caen, France
Aims. Coronary artery bypass grafting is conventionally considered the
standard treatment for significant left main coronary artery (LMCA) disease.
The management of severe coronary artery disease in the octogenarians is still
highly debated. The aim of this study was to appreciate safety and effective-
ness of percutaneaous coronary intervention (PCI) in octogenarians who were
denied by the heart team for surgical revascularization.
Methods and Results. The study included 70 consecutive patients
80 years of age who had undergone PCI for the treatment of LMCA and
who were primary denied by our center’s heart team for surgical revascular-
ization. In our study mean age was 83.4 ± 2.6 years [range 80-89]. Mean
Euroscore was 21.1 ± 16.7 and mean Syntax score was 28.6 ± 8.7. Ten (14%)
were treated with LMCA PCI in the context of ST-segment Elevation Myo-
cardial Infarction (STEMI). Overall in-hospital mortality was 11%. There
were two cases of fatal stent thrombosis at 2 and 7 days respectively after
DES implantation. Mean follow-up time was 27.2 ± 24.9 months [range 4-80
months]. Overall mortality at the end of follow-up was 28%. Cardiac death
was found in 18 patients and 2 patients died from terminal renal insufficiency.
2 other patients (3%) presented with a new STEMI, 7 (10%) with a new non-
STEMI, 13 (19%) with heart failure and 2 (3%) had minor hemorrhage. There
was a percutaneous target vessel revascularization in 7 (10%) patients. During
follow-up, the total major adverse cerebral and cardiovascular event
(MACCE) was 48.5%. Distal LMCA disease and male sex were independent
factors predicting mortality (p<0.05). 
Conclusions. Stent implantation was technically feasible and relatively
safely applied for the treatment of LMCA disease in octogenarian who were
refused for surgery and who represented a high risk population for PCI and
coronary events. Despite a high rate of MACCE, the clinical long term out-
come seems good for this specific population with heavy basal status.
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CYP2C19 but not PON1 genetic variants influence clopidogrel pharma-
cokinetics, pharmacodynamics and clinical efficacy in post-myocardial
infarction patients
Jean-Philippe Collet, Jean-Sébastien Hulot [Orateur] , Guillaume Cayla,
Johanne Silvain, Anne Bellemain, Farzin Beygui, Olivier Barthelemy, Fré-
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Background: Reduced concentrations of clopidogrel active metabolite
have been associated with diminished platelet inhibition and higher rates of
adverse cardiovascular events. Paraoxonase-1 (PON1) has recently been pro-
posed as a key enzyme for clopidogrel metabolic activation. We tested the
effects of PON1 polymorphisms on clopidogrel pharmacokinetics (PK) and
pharmacodynamics (PD), and the occurrence of cardiovascular outcomes in
young post-MI patients treated with clopidogrel.
Methods and Results: We genotyped PON1 (Q192R and L55M) and
CYP2C19 variants in 106 patients enrolled in the PK/PD CLOVIS-2 trial.
Patients were randomly exposed to 300mg or 900mg clopidogrel loading dose
in a cross-over study design. Clopidogrel active metabolite isomer H4 (clopi-
H4) and platelet function testing were measured serially post-loading dose.
There was no significant association between PON1 Q192R or L55M and
clopi-H4 formation or antiplatelet response to clopidogrel following either
loading dose. Using multivariable linear regression analyses, the CYP2C19*2
allele was the only predictor of clopi-H4 generation and platelet response irre-
spective of the platelet function assay. CYP2C19 loss-of-function but not
PON1 variants were significantly associated with increased risk of major car-
diovascular events (death, myocardial infarction and urgent coronary revascu-
larization) occurring during long-term clopidogrel exposure in 371 young
post-MI patients (<45 years) enrolled in the AFIJI cohort: CYP2C19 loss-of-
function allele carrier vs non carrier, HR 2.26 95%CI [1.15-4.41], p=0.02;
PON1 QQ192 vs QR/RR192, HR 1.03 95%CI [0.50-2.11], p=0.93; PON1
MM55 vs ML/LL55, HR 1.52 95%CI [0.75-3.08], p=0.24. 
Conclusion: Our study does not confirm that PON1 Q192R or L55M can
influence clopidogrel PK or PD in post-MI patients.
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Magnetocardiographic indices in assessment of patients with myocar-
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Aims: To assess ability of different magnitocardiogtaphic (MCG) indices
to discriminate between ischemic changes of electrophysiologic properties of
myocardium early after STE AMI and non-ischemic changes.
Methods: 32 pts with STE AMI (21 pts with ischemia on stress test – 1st
group and 11 pts without ischemia – 2nd group examined on 7-10th day after
STE AMI) , 32 pts with myocarditis (3rd group) and 34 healthy (4th group)
were evaluated . All patients had neither conduction abnormalities, ischemic
changes on resting ECG, nor LV hypertrophy, systolic dysfunction on
EchoCG. Healthy and AMI pts had exercise test on the same day with MCG.
Averaged deviations of largest vectors of current density distributions (CDD)
on ST slope starting at 60 ms from J to Tapex (first half of this ST portion –
D1, second half – D2), second portion of Ta-Te (D4) and differences in direc-
tions of vectors of CDD on R and Tapex (delta RTa), ratios between global
CDD on peak R to that on Tapex (GCDD-RTa) were assessed.
Results: In 1st, 2nd, 3rd and 4th groups median D1 were 9.0, 5.0 ,3.0, and
2.25 grads respectively, p<0.05; median D2 were 11.9, 5.3 , 3.5, and 1.60
grads, p<0.01; D4 were 12.3, 6.3 , 7.3, and 5.0 grads, p<0.05; median delta
RTa were 47.0, 32.5, 22.5 and 12.5 grads respectively, p<0,01. Best sensitivity
(91%) and specificity (71% and 76%) in discerning patients with and without
ischemia after MI were D2> 8.1 and delta RT >69.5 grads. 
Of parameters consistent with myocarditis was ratio GCDD-RTa (In 1st,
2nd, 3rd and 4th groups median GCDD-RTa 3.24, 4.01, 7.13 and 5.0 respec-
tively, p<0,01 between 3rd group and other study groups) which did not differ
significantly in STEMI patients. 
Conclusion: MCG is informative for assessment of patients with and
without coronary artery disease. MCG is capable of detection changes in elec-
trophysiologic properties in myocardium susceptible to ischemia and may be
used to select patients with STE MI who need revascularization. 
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MEHRAN bleeding risk scores to predict major bleeding complica-
tions among Tunisian patients with ACS
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mami (2), Sami Gargouri (2), Samira Chine (2), Sonia Marrakchi (2), Zied Bel
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(2) CHU A. Mami, Cardiologie, Ariana, Tunisie
Background: Bleeding is a major complication in patients treated for acute
coronary syndromes (ACS) with antithrombotic and invasive therapies. Con-
sequently, the benefit of such therapies should be balanced against the poten-
tial risk of hemorrhagic complications. CRUSADE and more recently
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MEHRAN models provide two risk scores that predict the likelihood of major
bleeding in patients hospitalized with ACS.
The aim of this studY: was to evaluate the performance of CRUSADE
AND MEHRAN risk scores to predict in-hospital major bleeding in a contem-
porary cohort of patients hospitalized for ACS in Tunisia.
Methods and results: The study subjects were 205 consecutive patients
admitted to our center between January 2010 and June 2010 with ACS. For
each patient, we calculated both the CRUSADE AND MEHRAN risk score
and evaluated its discrimination by the C statistic. 
By CRUSADE and MEHRAN risk scores, our patients were classified as high
or very high risk of major bleeding in 46.3%, 32.2% of cases, respectively.
The overall incidence of in-hospital bleeding events and major bleeding
(TIMI major definition) was 19.5%, 3.9%, respectively. The major bleeding
rate increased with the CRUSADE risk category: very low, 0%; low, 0%;
moderate, 3.8%; high, 4.0%; and very high, 13.3% (P=0.004). A stepwise
increase in rates of major bleeding with increasing MEHRAN score was also
noted (0%, 0%, 4.2% vs 9.9%; p=0.01). CRUSADE and MEHRAN risk
scores demonstrated a high performance for predicting in-hospital major
bleeding (c-statistic=0.86 and 0.83, respectively).
Conclusions: In routine clinical practice, bleeding is a relatively frequent
non-cardiac complication of contemporary therapy for ACS. These two scores
discriminate major bleeding risk and are both potentially useful in clinical
decision-making during ACS.
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Coronary stenting and surgery, a complex situation to manage. Use-
fulness of endothelial progenitor cells capture 
Philippe Longère, François Vochelet, Alain Tavildari, Marie Rose Cler-
geau, Bertrand Olive, Jean-Marc Pigassou, Luc Maillard [Orateur] 
Clinique Axium, Cardiologie, Aix-en-Provence, France
Background: Dealing with thrombotic risk of stent occlusion and hemor-
rhagic risk of surgery is not well documented in literature. Endothelial progen-
itor cells (EPCs), have been demonstrated to achieve a complete and
functional reendothelialization of expended coronary stent in 48 hours in
animal model. EPCs are captured by antibodies and immobilized on the stent
surface of the Genous stent (Orbus Medical). 
Method: 11 patients, 7 male, 4 female, 77.4+/–7.37 year old, presented an
acute coronary syndrome with severe coronary artery lesions and an urgent
surgical indication underwent PTCA with exclusive one or more Genous stent
(Orbus Medical). Single unique bolus of 10 mg/kg of clopidogrel associated
to 2 mg/kg of aspirin was given at least 6 hours prior PTCA. Surgery was
planned to be performed at day 5 following half pool platelet renewal. Inform
consent was obtained for all patients. 
Results: 1.72+/–0.78 stent was implanted for a total length of 28+/–12 mm
and a mean diameter of 3.0+/–0.5 mm. All target selected lesions included
left main (n=1), LAD (n=9), CX (n=3), RCA (n=6) were treated with angi-
ographic success. Mean ventricular ejection fraction was 55.0+/–0.5. Sur-
gery was performed in average at day 5 under aspirin alone (2 mg/kg) with
success of the planed surgical act (colectomy, prostatectomy, cholester-
olemy, mammectomy, gastrectomy, peripheral arterial graft) with no com-
plication. Intra venous nitrate was used for patients presenting incomplete
revascularization and distal lesions. Only one patient needed a blood trans-
fusion. At one month no event was observed (death, myocardial infarction,
repeat PTCA, cerebral event, stent thrombosis). 
Conclusion: Single bolus of clopidogrel for high risk evolutive coronary
artery lesions treated with Genous stent allow a surgical act at day 5 under
aspirin alone in good condition with no complication in this short series.
Those preliminary data can serve as an impetus for multi-center studies.
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Clopidogrel and statins: assessing a potential drug-drug interaction
Leila Abid [Orateur] , Lobna Laroussi, Olfa Zaghdène, Amine Bahloul,
Mourad Hentati, Samir Kammoun
Hôpital Hédi Chaker, Cardiologie, Sfax, Tunisie
Background: Clopidogrel and statins are frequently administered in
patients with ischemic heart disease or other atherothrombotic manifestations
and are effective in the prevention of cardiovascular disease. Clopidogrel is a
pro-drug metabolised in the liver to the active compound which inhibits the
P2Y (12) ADP platelet receptor. The aim of this study was to assess the asso-
ciation between the loss-of-function cytochrome P450 2C19 (CYP2C19)*2
variant, the use of statins which are metabolized by the CYP3A4 system and
ischemic outcomes (major adverse cardiovascular events [MACE]) in patients
treated with clopidogrel.
Methods: Between May 2009, and september 2010, 100 patients who
underwent a percutaneous coronary intervention (PCI) and were exposed to
clopidogrel treatment for at least one month, were enrolled in our study. They
underwent CYP2C19*2 determination. The primary endpoint was a composite
of death, myocardial infarction, and urgent coronary revascularisation occur-
ring during exposure to clopidogrel.
Results: 94% of our patients were on statins. Among these patients, 57%
were on statins metabolized by CYP3A4 (simvastatin or atorvastatin) and 37%
in statin not metabolized by CYP 3A4 (Rosuvastatin, Fluvastatin and Pravas-
tatin). Statins metabolized by CYP3A4 have no effect on the occurrence of
MACE under clopidogrel (p=0, 18). In the group of patients on statins metab-
olized by CYP3A4, no statistically significant difference was observed
regarding the occurrence of intra hospital MACE according to genetic profile
(11, 1% in the non mutated group versus 25 % in the mutated group).
Conclusion: The results of our study are consistent with those of the liter-
ature and have not shown any association between major cardiovascular
events and the use of statins metabolized by CYP3A4, this genotype.
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The C93T and G121A polymorphisms of the LPA gene is not associa-
ted with susceptibility to acute myocardial infarction
Soumira Mehri, Sonia Hammami [Orateur], Amel Nkbi, Nadia Koubaa,
Mohamed Hammami
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liques, Monastir, Tunisie
Background: Acute myocardial infarction (AMI) is the clinical manifesta-
tion of the chronic development of coronary artery atheroma, with the final
process of plaque rupture and coronary thrombosis. Plasma lipoprotein (a)
(Lp(a)) levels are mainly genetically determined. The C93T and G121A poly-
morphisms are a naturally occurring variant of the LPA gene that may influ-
ence Lp(a) concentration. The role of Lp(a) in the pathogenesis of myocardial
infarction has not been established.
Methods: A one hundred sixty-eight AMI patients compared to 169
healthy controls.
Results: No association between LPA C93T genotypes and AMI was
found. The frequencies of the GG, GA and AA genotypes of LPA G121A
polymorphism were not significantly different in AMI patients and in healthy
controls (45.2 %, 48.2%, 6.6 % vs 41.7 %, 49.4 %, 8.9%, P=0.880). In multi-
variate logistic regression analysis with covariates including traditional risk
factors (diabetes, hypertension, smoking and cholesterol) and, The C93T and
G121A polymorphisms, hypertension was independently associated with
increased risk of AMI (OR=3.5, P=0.044). 
Conclusion: The C93T and G121A polymorphisms of the LPA gene is not
associated with susceptibility to acute myocardial infarction
